Quarterly report pursuant to Section 13 or 15(d)

Related Party Matters (Details)

v3.23.2
Related Party Matters (Details)
3 Months Ended 4 Months Ended 6 Months Ended
Mar. 01, 2023
USD ($)
Feb. 28, 2023
USD ($)
May 18, 2022
USD ($)
shares
Mar. 01, 2022
USD ($)
Jun. 30, 2023
USD ($)
Jun. 30, 2022
USD ($)
Apr. 30, 2021
agreement
Jun. 30, 2023
USD ($)
Jun. 30, 2022
USD ($)
Dec. 31, 2022
USD ($)
Jan. 31, 2018
Related Party Transaction [Line Items]                      
Research and development expense         $ 1,788,434 $ 1,427,154   $ 2,973,314 $ 2,692,807    
Other current liabilities         849,333     849,333   $ 1,366,994  
Exclusive Sponsored Research Agreement | EHBE                      
Related Party Transaction [Line Items]                      
Prepaid expense - related party         50,000     50,000   50,000  
Research and development expense         0 50,000   50,000 100,000    
ESRA Agreement, Screening Platform For Anteroposterior Ocular Diseases                      
Related Party Transaction [Line Items]                      
Research and development expense         10,967 39,167   103,913 120,000    
Other current liabilities         0     0   7,835  
Accounts payable         47,001     47,001   47,001  
ESRA Agreement, Screening Platform For Anteroposterior Ocular Diseases | EHBE                      
Related Party Transaction [Line Items]                      
Annual retainer amount       $ 190,500              
Consulting Agreement                      
Related Party Transaction [Line Items]                      
Accounts payable         1,772     1,772   12,511  
Dr. Avtar Dhillon | Independent Contractor Agreement                      
Related Party Transaction [Line Items]                      
Accrued expense under agreement         0 48,908   0 87,926    
Prepaid expense - related party                   $ 8,056  
Independent Contractor Services Agreement | Jim Heppell                      
Related Party Transaction [Line Items]                      
Initial term of research agreement (in years)     1 year                
Monthly fee     $ 6,300                
Increase In monthly fee     $ 16,600                
Termination payment $ 74,700                    
Granted (in shares) | shares     4,000,000                
Severance expense               0      
Collaborative Research Agreement | Emerald Health Biotechnology Espana, S.L.U.                      
Related Party Transaction [Line Items]                      
Number of collaborative research agreements | agreement             2        
Collaborative Research Agreement | Emerald Health Biotechnology Espana, S.L.U. | Emerald Health Research, Inc                      
Related Party Transaction [Line Items]                      
Subsidiary ownership (as a percent)             100.00%        
Consulting Agreement | Dr. Avtar Dhillon                      
Related Party Transaction [Line Items]                      
Fees incurred under agreement         $ 11,686 $ 32,369   $ 10,779 $ 19,374    
Consulting Agreement | Immediate Family Member of Management or Principal Owner                      
Related Party Transaction [Line Items]                      
Annual rate per hour   $ 73                  
Termination notice period (in days)   15 days                  
Emerald                      
Related Party Transaction [Line Items]                      
Ownership (as a percentage)                     17.40%